About: Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights
Creator	Janakiraman, Kumar Kandasamy, Ruckmani Krishnaswami, Venkateshwaran Natesan, Subramanian Rajendran, Vijaya
source	Elsevier; Medline; PMC
abstract	Rheumatoid arthritis (RA) is the most common complex multifactorial joint related autoimmune inflammatory disease with unknown etiology accomplished with increased cardiovascular risks. RA is characterized by the clinical findings of synovial inflammation, autoantibody production, and cartilage/bone destruction, cardiovascular, pulmonary and skeletal disorders. Pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and IL-10 were responsible for the induction of inflammation in RA patients. Drawbacks such as poor efficacy, higher doses, frequent administration, low responsiveness, and higher cost and serious side effects were associated with the conventional dosage forms for RA treatment. Nanomedicines were recently gaining more interest towards the treatment of RA, and researchers were also focusing towards the development of various anti-inflammatory drug loaded nanoformulations with an aid to both actively/passively targeting the inflamed site to afford an effective treatment regimen for RA. Alterations in the surface area and nanoscale size of the nanoformulations elicit beneficial physical and chemical properties for better pharmacological activities. These drug loaded nanoformulations may enhances the solubility of poorly water soluble drugs, improves the bioavailability, affords targetability and may improve the therapeutic activity. In this regimen, the present review focus towards the novel nanoparticulate formulations (nanoparticles, nanoemulsions, solid lipid nanoparticles, nanomicelles, and nanocapsules) utilized for the treatment of RA. The recent advancements such as siRNA, peptide and targeted based nanoparticulate systems for RA treatment were also discussed. Special emphasis was provided regarding the pathophysiology, prevalence and symptoms towards the development of RA.
has issue date	2018-09-15(xsd:dateTime)
bibo:doi	10.1016/j.mtcomm.2018.09.011
bibo:pmid	32289062
has license	no-cc
sha1sum (hex)	c1551f64bd095d1920556e4354aa3a4d86c2a5b5
schema:url	https://doi.org/10.1016/j.mtcomm.2018.09.011
resource representing a document's title	Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights
has PubMed Central identifier	PMC7104012
has PubMed identifier	32289062
schema:publication	Mater Today Commun
resource representing a document's body	covid:c1551f64bd095d1920556e4354aa3a4d86c2a5b5#body_text
is schema:about of	named entity 'bioavailability' named entity 'surface area' named entity 'physical' named entity 'risks' named entity 'nanoemulsions' named entity 'These' named entity 'nanoparticulate' named entity 'production' named entity 'improve' named entity 'solid' named entity 'bone' named entity 'effective' named entity 'RELATED' named entity 'TREATMENT REGIMEN' named entity 'IL-6' named entity 'HIGHER' named entity 'INFLAMMATION' named entity 'THESE' named entity 'AID' named entity 'RISKS' named entity 'SYMPTOMS' named entity 'EFFICACY' named entity 'DRUG' named entity 'IL-8' named entity 'INTEREST' named entity 'IL-1' named entity 'INFLAMMATORY' named entity 'ACTIVITY' named entity 'ADMINISTRATION' named entity 'LOW' named entity 'POORLY' named entity 'NANOCAPSULES' named entity 'CLINICAL FINDINGS' named entity 'MULTIFACTORIAL' named entity 'PATHOPHYSIOLOGY' named entity 'ASSOCIATED WITH' named entity 'DOSES' named entity 'SYNOVIAL' named entity 'NANO' named entity 'EFFECTIVE' named entity 'FOCUS' named entity 'POOR' named entity 'COST' named entity 'REGIMEN' named entity 'INFLAMMATORY DISEASE' covid:arg/c1551f64bd095d1920556e4354aa3a4d86c2a5b5 named entity 'DEVELOPMENT' named entity 'SIZE' named entity 'AUTOANTIBODY PRODUCTION' named entity 'RHEUMATOID ARTHRITIS' named entity 'MATERIALS' named entity 'TREATMENT' named entity 'NOVEL' named entity 'SITE' named entity 'LIPID' named entity 'INDUCTION' named entity 'INFLAMED' named entity 'VARIOUS' named entity 'CHEMICAL PROPERTIES' named entity 'LOADED' named entity 'PHYSICAL' named entity 'ACTIVITIES' named entity 'ALTERATIONS' named entity 'SOLUBLE' named entity 'RESPONSIVENESS' named entity 'AUTOIMMUNE' named entity 'PHARMACOLOGICAL' named entity 'PEPTIDE' named entity 'ANTI-INFLAMMATORY DRUG' named entity 'WATER' named entity 'RESPONSIBLE' named entity 'SPECIAL' named entity 'GAINING' named entity 'JOINT' named entity 'CARTILAGE' named entity 'SKELETAL' named entity 'SYSTEMS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software